Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 10, 2014

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Neoplasm in the LiverMetastatic Malignant Solid NeoplasmUnresectable Solid Neoplasm
Interventions
DRUG

Trametinib

Given PO

Trial Locations (11)

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

48201

Wayne State University/Karmanos Cancer Institute, Detroit

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

77030

M D Anderson Cancer Center, Houston

95817

University of California Davis Comprehensive Cancer Center, Sacramento

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02070549 - Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction | Biotech Hunter | Biotech Hunter